Triple

T11074711
Position Surface form Disambiguated ID Type / Status
Subject Docetaxel E261833 entity
Predicate oftenUsedInCombinationWith P4791 FINISHED
Object cyclophosphamide E261829 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: cyclophosphamide | Statement: [Docetaxel, oftenUsedInCombinationWith, cyclophosphamide]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: cyclophosphamide
Context triple: [Docetaxel, oftenUsedInCombinationWith, cyclophosphamide]
  • A. cyclophosphamide chosen
    Cyclophosphamide is a widely used alkylating chemotherapy and immunosuppressive drug commonly employed in the treatment of cancers and autoimmune diseases.
  • B. vincristine
    Vincristine is a chemotherapy medication, specifically a vinca alkaloid, widely used in combination regimens to treat various cancers including lymphomas and leukemias.
  • C. Alimta
    Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
  • D. mitoxantrone
    Mitoxantrone is an anthracenedione chemotherapeutic agent used primarily to treat certain cancers and multiple sclerosis by intercalating DNA and inhibiting topoisomerase II.
  • E. Zaltrap
    Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d6aa9983c08190b0ef61603b69feac completed April 8, 2026, 7:20 p.m.
NER Named-entity recognition batch_69d7994efb608190a81bc8c4d16ddbd0 completed April 9, 2026, 12:19 p.m.
NED1 Entity disambiguation (via context triple) batch_69e3c8cc77988190aad54f56dbd0f8cf completed April 18, 2026, 6:09 p.m.
Created at: April 8, 2026, 9:26 p.m.